Methotrexat Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, limiting the production of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition slows the proliferation of rapidly dividing cells, providing antineoplastic effects, and at lower doses modulates immune cell activity, offering immunosuppressive benefits.

The dosage of methotrexate is individualized. A qualified prescriber determines the appropriate dose, frequency, and duration based on the specific indication, patient characteristics, and clinical response. No generic dosing information is provided here.

Methotrexate is classified as pregnancy category X because it is known to cause fetal harm and is contraindicated during pregnancy. It is also contraindicated while breastfeeding, as it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other immunosuppressants such as azathioprine, methotrexate offers a distinct mechanism by targeting folate metabolism, often providing stronger anti‑inflammatory effects in rheumatoid arthritis and psoriasis. Biologic agents act on specific cytokines and may be used when methotrexate is insufficient or not tolerated.

Methotrexat Ebewe should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow standard aseptic techniques when preparing for intravenous administration.

The product is supplied as an injectable solution for intravenous use. It is administered by a qualified healthcare professional, typically as a slow IV infusion or injection, according to the prescriber’s instructions and institutional protocols.

Serious adverse events include severe liver toxicity, pulmonary fibrosis or pneumonitis, and profound myelosuppression leading to infections or bleeding. Patients should be monitored regularly for liver enzymes, lung symptoms and blood counts, and any alarming signs should prompt immediate medical evaluation.

Methotrexat Ebewe is contraindicated in pregnant women, nursing mothers, and individuals with severe renal or hepatic impairment. Patients with known hypersensitivity to methotrexate or any component of the formulation should also avoid its use.